{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T20:22:22Z","timestamp":1790022142864,"version":"4.0.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":71,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82574429"],"award-info":[{"award-number":["82574429"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81973359"],"award-info":[{"award-number":["81973359"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2024A1515011452"],"award-info":[{"award-number":["2024A1515011452"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2023A1515012521"],"award-info":[{"award-number":["2023A1515012521"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011789","name":"Department of Science and Technology of Jilin Province","doi-asserted-by":"publisher","award":["20240404034ZP"],"award-info":[{"award-number":["20240404034ZP"]}],"id":[{"id":"10.13039\/501100011789","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chemotherapy resistance and intolerance present significant challenges in the effective treatment of acute myeloid leukemia (AML). However, the role of metabolic reprogramming, particularly lipid metabolic rewiring, in promoting chemotherapy resistance in leukemia has not been fully elucidated. Here, we found that multiple lipid metabolism processes are aberrantly activated in Ara-C resistant AML cells, accompanied by upregulation of JAK-STAT3 signaling and key lipid metabolic regulators, notably SREBP1 and CPT2. Additionally, we discovered W1307, a potent and highly selective STAT3 inhibitor, which demonstrated significant anti-tumor activity both in vitro and in vivo. Genetic and pharmacological inhibition of STAT3 simultaneously suppresses lipid synthesis and catabolism, leading to lipids metabolic disorder accompanied with lipids accumulation, ROS increase, lipid peroxidation and mitochondrial membrane potential decrease. Mechanistically, STAT3 binds to DNA response elements in the promoters of the lipid metabolism associated gene SREBF1 and CPT2, and regulates their expression. Furthermore, inhibition of STAT3 enhances the anti-tumor effect of Ara-C and sensitizes resistant AML cell line to Ara-C through disrupting lipid homeostasis and triggering lipotoxicity. Our findings highlight the critical role of STAT3-driven lipid metabolism reprogramming in chemoresistance. Furthermore, W1307 emerges as a promising therapeutic candidate to overcome chemoresistance in leukemia treatment.<\/jats:p>","DOI":"10.1038\/s41419-026-08988-4","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T14:44:31Z","timestamp":1781707471000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Targeting STAT3-mediated lipid metabolism reprogramming overcomes chemoresistance in acute myeloid leukemia"],"prefix":"10.1038","volume":"17","author":[{"given":"Keren","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianshan","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenjiao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayu","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shumin","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minyuan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongru","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiqin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiongjun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peibin","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinjian","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanxiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanyi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7320-5135","authenticated-orcid":false,"given":"Yandong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2395-2453","authenticated-orcid":false,"given":"Xiaolei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"8988_CR1","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/S0140-6736(18)31041-9","volume":"392","author":"NJ Short","year":"2018","unstructured":"Short NJ, Rytting ME, Cortes JE. Acute myeloid leukaemia. Lancet. 2018;392:593\u2013606.","journal-title":"Lancet"},{"key":"8988_CR2","doi-asserted-by":"publisher","first-page":"n2026","DOI":"10.1136\/bmj.n2026","volume":"375","author":"LF Newell","year":"2021","unstructured":"Newell LF, Cook RJ. Advances in acute myeloid leukemia. BMJ. 2021;375:n2026.","journal-title":"BMJ"},{"key":"8988_CR3","doi-asserted-by":"publisher","first-page":"4955","DOI":"10.3390\/ijms22094955","volume":"22","author":"GR Fajardo-Ordu\u00f1a","year":"2021","unstructured":"Fajardo-Ordu\u00f1a GR, Ledesma-Mart\u00ednez E, Agui\u00f1iga-S\u00e1nchez I, Mora-Garc\u00eda MdeL, Weiss-Steider B, Santiago-Osorio E. Inhibitors of chemoresistance pathways in combination with ara-c to overcome multidrug resistance in AML. a mini review. Int J Mol Sci. 2021;22:4955.","journal-title":"Int J Mol Sci"},{"key":"8988_CR4","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H D\u00f6hner","year":"2015","unstructured":"D\u00f6hner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373:1136\u201352.","journal-title":"N Engl J Med"},{"key":"8988_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00425-3","volume":"11","author":"H Kantarjian","year":"2021","unstructured":"Kantarjian H, Kadia T, DiNardo C, Daver N, Borthakur G, Jabbour E, et al. Acute myeloid leukemia: current progress and future directions. Blood Cancer J. 2021;11:41.","journal-title":"Blood Cancer J"},{"key":"8988_CR6","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1158\/2159-8290.CD-20-0844","volume":"10","author":"S-M Fendt","year":"2020","unstructured":"Fendt S-M, Frezza C, Erez A. Targeting metabolic plasticity and flexibility dynamics for cancer therapy. Cancer Discov. 2020;10:1797\u2013807.","journal-title":"Cancer Discov"},{"key":"8988_CR7","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1038\/s41568-021-00388-4","volume":"21","author":"AJ Hoy","year":"2021","unstructured":"Hoy AJ, Nagarajan SR, Butler LM. Tumour fatty acid metabolism in the context of therapy resistance and obesity. Nat Rev Cancer. 2021;21:753\u201366.","journal-title":"Nat Rev Cancer"},{"key":"8988_CR8","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41416-019-0650-z","volume":"122","author":"N Koundouros","year":"2020","unstructured":"Koundouros N, Poulogiannis G. Reprogramming of fatty acid metabolism in cancer. Br J Cancer. 2020;122:4\u201322.","journal-title":"Br J Cancer"},{"key":"8988_CR9","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41420-021-00744-1","volume":"7","author":"C Xu","year":"2021","unstructured":"Xu C, Zhang L, Wang D, Jiang S, Cao D, Zhao Z, et al. Lipidomics reveals that sustained SREBP-1-dependent lipogenesis is a key mediator of gefitinib-acquired resistance in EGFR-mutant lung cancer. Cell Death Discov. 2021;7:353.","journal-title":"Cell Death Discov"},{"key":"8988_CR10","doi-asserted-by":"publisher","first-page":"3405","DOI":"10.1016\/j.celrep.2019.11.008","volume":"29","author":"WW Feng","year":"2019","unstructured":"Feng WW, Wilkins O, Bang S, Ung M, Li J, An J, et al. CD36-mediated metabolic rewiring of breast cancer cells promotes resistance to HER2-targeted therapies. Cell Rep. 2019;29:3405\u201320.e5.","journal-title":"Cell Rep"},{"key":"8988_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02732-5","volume":"9","author":"AK Cotte","year":"2018","unstructured":"Cotte AK, Aires V, Fredon M, Limagne E, Derang\u00e8re V, Thibaudin M, et al. Lysophosphatidylcholine acyltransferase 2-mediated lipid droplet production supports colorectal cancer chemoresistance. Nat Commun. 2018;9:322.","journal-title":"Nat Commun"},{"key":"8988_CR12","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.cmet.2017.11.001","volume":"27","author":"T Wang","year":"2018","unstructured":"Wang T, Fahrmann JF, Lee H, Li Y-J, Tripathi SC, Yue C, et al. JAK\/STAT3-regulated fatty acid \u03b2-oxidation is critical for breast cancer stem cell self-renewal and chemoresistance. Cell Metab. 2018;27:136\u201350.e5.","journal-title":"Cell Metab"},{"key":"8988_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.aca.2022.339761","volume":"1206","author":"M Sun","year":"2022","unstructured":"Sun M, Chen X, Yang Z. Single cell mass spectrometry studies reveal metabolomic features and potential mechanisms of drug-resistant cancer cell lines. Anal Chim Acta. 2022;1206:339761.","journal-title":"Anal Chim Acta"},{"key":"8988_CR14","doi-asserted-by":"publisher","first-page":"8117","DOI":"10.1158\/0008-5472.CAN-09-3871","volume":"70","author":"E Rysman","year":"2010","unstructured":"Rysman E, Brusselmans K, Scheys K, Timmermans L, Derua R, Munck S, et al. De novo lipogenesis protects cancer cells from free radicals and chemotherapeutics by promoting membrane lipid saturation. Cancer Res. 2010;70:8117\u201326.","journal-title":"Cancer Res"},{"key":"8988_CR15","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.cmet.2008.07.007","volume":"8","author":"T Porstmann","year":"2008","unstructured":"Porstmann T, Santos CR, Griffiths B, Cully M, Wu M, Leevers S, et al. SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth. Cell Metab. 2008;8:224\u201336.","journal-title":"Cell Metab"},{"key":"8988_CR16","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1038\/onc.2015.179","volume":"35","author":"SJH Ricoult","year":"2016","unstructured":"Ricoult SJH, Yecies JL, Ben-Sahra I, Manning BD. Oncogenic PI3K and K-Ras stimulate de novo lipid synthesis through mTORC1 and SREBP. Oncogene. 2016;35:1250\u201360.","journal-title":"Oncogene"},{"key":"8988_CR17","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1038\/nrc3818","volume":"14","author":"H Yu","year":"2014","unstructured":"Yu H, Lee H, Herrmann A, Buettner R, Jove R. Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer. 2014;14:736\u201346.","journal-title":"Nat Rev Cancer"},{"key":"8988_CR18","doi-asserted-by":"publisher","first-page":"240","DOI":"10.3390\/cancers12010240","volume":"12","author":"M Brachet-Botineau","year":"2020","unstructured":"Brachet-Botineau M, Polomski M, Neubauer HA, Juen L, H\u00e9dou D, Viaud-Massuard M-C, et al. Pharmacological Inhibition of Oncogenic STAT3 and STAT5 Signaling in Hematopoietic Cancers. Cancers (Basel). 2020;12:240.","journal-title":"Cancers (Basel)"},{"key":"8988_CR19","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","volume":"15","author":"DE Johnson","year":"2018","unstructured":"Johnson DE, O\u2019Keefe RA, Grandis JR. Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer. Nat Rev Clin Oncol. 2018;15:234\u201348.","journal-title":"Nat Rev Clin Oncol"},{"key":"8988_CR20","doi-asserted-by":"publisher","first-page":"824","DOI":"10.7150\/thno.49600","volume":"11","author":"Q Zheng","year":"2021","unstructured":"Zheng Q, Dong H, Mo J, Zhang Y, Huang J, Ouyang S, et al. A novel STAT3 inhibitor W2014-S regresses human non-small cell lung cancer xenografts and sensitizes EGFR-TKI acquired resistance. Theranostics. 2021;11:824\u201340.","journal-title":"Theranostics"},{"key":"8988_CR21","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.ccell.2020.06.007","volume":"38","author":"R Siersb\u00e6k","year":"2020","unstructured":"Siersb\u00e6k R, Scabia V, Nagarajan S, Chernukhin I, Papachristou EK, Broome R, et al. IL6\/STAT3 signaling hijacks estrogen receptor \u03b1 enhancers to drive breast cancer metastasis. Cancer Cell. 2020;38:412\u201323.e9.","journal-title":"Cancer Cell"},{"key":"8988_CR22","first-page":"6659","volume":"62","author":"LB Mora","year":"2002","unstructured":"Mora LB, Buettner R, Seigne J, Diaz J, Ahmad N, Garcia R, et al. Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res. 2002;62:6659\u201366.","journal-title":"Cancer Res"},{"key":"8988_CR23","doi-asserted-by":"publisher","first-page":"5701","DOI":"10.1182\/blood-2010-04-280123","volume":"117","author":"MS Redell","year":"2011","unstructured":"Redell MS, Ruiz MJ, Alonzo TA, Gerbing RB, Tweardy DJ. Stat3 signaling in acute myeloid leukemia: ligand-dependent and -independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor. Blood. 2011;117:5701\u20139.","journal-title":"Blood"},{"key":"8988_CR24","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1182\/blood.2021013201","volume":"139","author":"ML Amaya","year":"2022","unstructured":"Amaya ML, Inguva A, Pei S, Jones C, Krug A, Ye H, et al. The STAT3-MYC axis promotes survival of leukemia stem cells by regulating SLC1A5 and oxidative phosphorylation. Blood. 2022;139:584\u201396.","journal-title":"Blood"},{"key":"8988_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2022.113112","volume":"415","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Guo H, Zhang Z, Lu W, Zhu J, Shi J. IL-6 promotes chemoresistance via upregulating CD36 mediated fatty acids uptake in acute myeloid leukemia. Exp Cell Res. 2022;415:113112.","journal-title":"Exp Cell Res"},{"key":"8988_CR26","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1158\/2159-8290.CD-16-0441","volume":"7","author":"T Farge","year":"2017","unstructured":"Farge T, Saland E, de Toni F, Aroua N, Hosseini M, Perry R, et al. Chemotherapy-resistant human acute myeloid leukemia cells are not enriched for leukemic stem cells but require oxidative metabolism. Cancer Discov. 2017;7:716\u201335.","journal-title":"Cancer Discov"},{"key":"8988_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2022.102317","volume":"52","author":"S Ouyang","year":"2022","unstructured":"Ouyang S, Li H, Lou L, Huang Q, Zhang Z, Mo J, et al. Inhibition of STAT3-ferroptosis negative regulatory axis suppresses tumor growth and alleviates chemoresistance in gastric cancer. Redox Biol. 2022;52:102317.","journal-title":"Redox Biol"},{"key":"8988_CR28","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1002\/ijc.2910420517","volume":"42","author":"GL May","year":"1988","unstructured":"May GL, Wright LC, Dyne M, Mackinnon WB, Fox RM, Mountford CE. Plasma membrane lipid composition of vinblastine sensitive and resistant human leukaemic lymphoblasts. Int J Cancer. 1988;42:728\u201333.","journal-title":"Int J Cancer"},{"key":"8988_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2019.100670","volume":"49","author":"J Kopecka","year":"2020","unstructured":"Kopecka J, Trouillas P, Ga\u0161parovi\u0107 A\u010c, Gazzano E, Assaraf YG, Riganti C. Phospholipids and cholesterol: Inducers of cancer multidrug resistance and therapeutic targets. Drug Resist Updat. 2020;49:100670.","journal-title":"Drug Resist Updat"},{"key":"8988_CR30","doi-asserted-by":"publisher","first-page":"31189","DOI":"10.1073\/pnas.2017152117","volume":"117","author":"J Yi","year":"2020","unstructured":"Yi J, Zhu J, Wu J, Thompson CB, Jiang X. Oncogenic activation of PI3K-AKT-mTOR signaling suppresses ferroptosis via SREBP-mediated lipogenesis. Proc Natl Acad Sci USA. 2020;117:31189\u201397.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8988_CR31","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/mco2.27","volume":"2","author":"Y Fu","year":"2020","unstructured":"Fu Y, Zou T, Shen X, Nelson PJ, Li J, Wu C, et al. Lipid metabolism in cancer progression and therapeutic strategies. MedComm (2020). 2020;2:27\u201359.","journal-title":"MedComm (2020)"},{"key":"8988_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/emm.2016.157","volume":"49","author":"LD Ly","year":"2017","unstructured":"Ly LD, Xu S, Choi S-K, Ha C-M, Thoudam T, Cha S-K, et al. Oxidative stress and calcium dysregulation by palmitate in type 2 diabetes. Exp Mol Med. 2017;49:e291.","journal-title":"Exp Mol Med"},{"key":"8988_CR33","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.lfs.2017.11.019","volume":"192","author":"AH de Mello","year":"2018","unstructured":"de Mello AH, Costa AB, Engel JDG, Rezin GT. Mitochondrial dysfunction in obesity. Life Sci. 2018;192:26\u201332.","journal-title":"Life Sci"},{"key":"8988_CR34","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.semcdb.2017.05.023","volume":"80","author":"M Jn","year":"2018","unstructured":"Jn M, Tg C. ROS signalling in the biology of cancer. Semin Cell Develop Biol. 2018;80:50\u201364.","journal-title":"Semin Cell Develop Biol"},{"key":"8988_CR35","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/nature21686","volume":"544","author":"S Han","year":"2017","unstructured":"Han S, Schroeder EA, Silva-Garc\u00eda CG, Hebestreit K, Mair WB, Brunet A. Mono-unsaturated fatty acids link H3K4me3 modifiers to C. elegans lifespan. Nature. 2017;544:185\u201390.","journal-title":"Nature"},{"key":"8988_CR36","doi-asserted-by":"publisher","first-page":"4179","DOI":"10.1182\/blood-2008-07-172007","volume":"113","author":"G Juliusson","year":"2009","unstructured":"Juliusson G, Antunovic P, Derolf A, Lehmann S, M\u00f6llg\u00e5rd L, Stockelberg D, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood. 2009;113:4179\u201387.","journal-title":"Blood"},{"key":"8988_CR37","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1182\/blood.2022018092","volume":"141","author":"SK Mishra","year":"2023","unstructured":"Mishra SK, Millman SE, Zhang L. Metabolism in acute myeloid leukemia: mechanistic insights and therapeutic targets. Blood. 2023;141:1119\u201335.","journal-title":"Blood"},{"key":"8988_CR38","doi-asserted-by":"publisher","first-page":"8505","DOI":"10.3390\/ijms21228505","volume":"21","author":"C Gurnari","year":"2020","unstructured":"Gurnari C, Pagliuca S, Visconte V. Deciphering the therapeutic resistance in acute myeloid leukemia. Int J Mol Sci. 2020;21:8505.","journal-title":"Int J Mol Sci"},{"key":"8988_CR39","doi-asserted-by":"publisher","first-page":"5503","DOI":"10.1158\/0008-5472.CAN-16-3062","volume":"77","author":"S Tadros","year":"2017","unstructured":"Tadros S, Shukla SK, King RJ, Gunda V, Vernucci E, Abrego J, et al. De novo lipid synthesis facilitates gemcitabine resistance through endoplasmic reticulum stress in pancreatic cancer. Cancer Res. 2017;77:5503\u201317.","journal-title":"Cancer Res"},{"key":"8988_CR40","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s13046-025-03463-y","volume":"44","author":"X Jin","year":"2025","unstructured":"Jin X, He X, Huang R, Liu Q, Wang L, Bai X, et al. SNRPB\/CCNB1 axis promotes hepatocellular carcinoma progression and cisplatin resistance through enhancing lipid metabolism reprogramming. J Exp Clin Cancer Res: CR. 2025;44:211.","journal-title":"J Exp Clin Cancer Res: CR"},{"key":"8988_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56675-3","volume":"16","author":"V Van den Bossche","year":"2025","unstructured":"Van den Bossche V, Vignau J, Vigneron E, Rizzi I, Zaryouh H, Wouters A, et al. PPAR\u03b1-mediated lipid metabolism reprogramming supports anti-EGFR therapy resistance in head and neck squamous cell carcinoma. Nat Commun. 2025;16:1237.","journal-title":"Nat Commun"},{"key":"8988_CR42","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1186\/s13046-025-03600-7","volume":"44","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Wang X, Wang J, Ma K, Jia L, Liu B, et al. STARD4 suppresses tumorigenesis and attenuates enzalutamide resistance via lipid metabolic reprogramming and AR stabilization in prostate cancer. J Exp Clin Cancer Res: CR. 2025;44:318.","journal-title":"J Exp Clin Cancer Res: CR"},{"key":"8988_CR43","doi-asserted-by":"publisher","first-page":"e11606.","DOI":"10.1002\/advs.202511606","volume":"13","author":"X Qi","year":"2026","unstructured":"Qi X, Guo Y, Yang Y, Wang H, Yang X, Song R, et al. PDZK1-ULK1 axis triggers lipophagy to inhibit tumor progression and sunitinib resistance in clear cell renal cell carcinoma. Adv Sci (Weinh). 2026;13:e11606.","journal-title":"Adv Sci (Weinh)"},{"key":"8988_CR44","doi-asserted-by":"publisher","first-page":"823","DOI":"10.18632\/aging.100232","volume":"2","author":"M Demaria","year":"2010","unstructured":"Demaria M, Giorgi C, Lebiedzinska M, Esposito G, D\u2019Angeli L, Bartoli A, et al. A STAT3-mediated metabolic switch is involved in tumour transformation and STAT3 addiction. Aging (Albany NY). 2010;2:823\u201342.","journal-title":"Aging (Albany NY)"},{"key":"8988_CR45","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41568-022-00537-3","volume":"23","author":"Y-J Li","year":"2023","unstructured":"Li Y-J, Zhang C, Martincuks A, Herrmann A, Yu H. STAT proteins in cancer: orchestration of metabolism. Nat Rev Cancer. 2023;23:115\u201334.","journal-title":"Nat Rev Cancer"},{"key":"8988_CR46","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20150240","volume":"36","author":"M Wajner","year":"2015","unstructured":"Wajner M, Amaral AU. Mitochondrial dysfunction in fatty acid oxidation disorders: insights from human and animal studies. Biosci Rep. 2015;36:e00281.","journal-title":"Biosci Rep"},{"key":"8988_CR47","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/nrendo.2015.129","volume":"11","author":"CS McCoin","year":"2015","unstructured":"McCoin CS, Knotts TA, Adams SH. Acylcarnitines-old actors auditioning for new roles in metabolic physiology. Nat Rev Endocrinol. 2015;11:617\u201325.","journal-title":"Nat Rev Endocrinol"},{"key":"8988_CR48","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.devcel.2017.06.003","volume":"42","author":"TB Nguyen","year":"2017","unstructured":"Nguyen TB, Louie SM, Daniele JR, Tran Q, Dillin A, Zoncu R, et al. DGAT1-Dependent Lipid Droplet Biogenesis Protects Mitochondrial Function during Starvation-Induced Autophagy. Dev Cell. 2017;42:9\u201321.e5.","journal-title":"Dev Cell"},{"key":"8988_CR49","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1182\/blood.V99.1.252","volume":"99","author":"M Benekli","year":"2002","unstructured":"Benekli M, Xia Z, Donohue KA, Ford LA, Pixley LA, Baer MR, et al. Constitutive activity of signal transducer and activator of transcription 3 protein in acute myeloid leukemia blasts is associated with short disease-free survival. Blood. 2002;99:252\u20137.","journal-title":"Blood"},{"key":"8988_CR50","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1182\/blood.V87.5.1692.1692","volume":"87","author":"V Gouilleux-Gruart","year":"1996","unstructured":"Gouilleux-Gruart V, Gouilleux F, Desaint C, Claisse JF, Capiod JC, Delobel J, et al. STAT-related transcription factors are constitutively activated in peripheral blood cells from acute leukemia patients. Blood. 1996;87:1692\u20137.","journal-title":"Blood"},{"key":"8988_CR51","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1182\/blood-2012-04-421925","volume":"121","author":"MS Redell","year":"2013","unstructured":"Redell MS, Ruiz MJ, Gerbing RB, Alonzo TA, Lange BJ, Tweardy DJ, et al. FACS analysis of Stat3\/5 signaling reveals sensitivity to G-CSF and IL-6 as a significant prognostic factor in pediatric AML: a Children\u2019s Oncology Group report. Blood. 2013;121:1083\u201393.","journal-title":"Blood"},{"key":"8988_CR52","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1111\/cas.12683","volume":"106","author":"M Ogura","year":"2015","unstructured":"Ogura M, Uchida T, Terui Y, Hayakawa F, Kobayashi Y, Taniwaki M, et al. Phase I study of OPB-51602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed\/refractory hematological malignancies. Cancer Sci. 2015;106:896\u2013901.","journal-title":"Cancer Sci"},{"key":"8988_CR53","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1007\/s40265-017-0759-4","volume":"77","author":"JM Hubbard","year":"2017","unstructured":"Hubbard JM, Grothey A. Napabucasin: An Update on the First-in-Class Cancer Stemness Inhibitor. Drugs. 2017;77:1091\u2013103.","journal-title":"Drugs"},{"key":"8988_CR54","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.ccell.2019.10.002","volume":"36","author":"L Bai","year":"2019","unstructured":"Bai L, Zhou H, Xu R, Zhao Y, Chinnaswamy K, McEachern D, et al. A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo. Cancer Cell. 2019;36:498\u2013511.e17.","journal-title":"Cancer Cell"},{"key":"8988_CR55","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s40425-018-0436-5","volume":"6","author":"MJ Reilley","year":"2018","unstructured":"Reilley MJ, McCoon P, Cook C, Lyne P, Kurzrock R, Kim Y, et al. STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial. J Immunother Cancer. 2018;6:119.","journal-title":"J Immunother Cancer"},{"key":"8988_CR56","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1182\/blood-2013-07-517987","volume":"123","author":"DMS Hossain","year":"2014","unstructured":"Hossain DMS, Dos Santos C, Zhang Q, Kozlowska A, Liu H, Gao C, et al. Leukemia cell-targeted STAT3 silencing and TLR9 triggering generate systemic antitumor immunity. Blood. 2014;123:15\u201325.","journal-title":"Blood"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08988-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08988-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08988-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:02:51Z","timestamp":1787788971000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08988-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8988"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08988-4","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"assertion":[{"value":"29 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The animal procedures were approved by the Institutional Animal Care and Use Committee of Sun Yat-sen University (SYSU-IACUC-2022000685, SYSU-IACUC- 2022003072) and followed the Guide for the Care and Use of Laboratory Animals.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"755"}}